Introduction
============

Thymomas are rare tumors arising from the epithelial cells of the thymus, commonly associated with myasthenia gravis or other autoimmune disorders.^[@bib1]^ The WHO classification system categorizes thymomas (type A, B1, B2, B3 and AB) and thymic carcinoma (type C) according to morphology, degree of atypia, histological similarity to normal thymic cells and degree of lymphocyte infiltration.^[@bib2]^ Thymomas are staged (stage I, IIA, IIB, III, IVA and IVB) according to degree of encapsulation and anatomic extent of disease with encapsulation decreasing and dispersion from the thymus increasing with stage.^[@bib3]^ Late stage thymomas are very rare and tend to locally recur rather than metastasize. Type B3 thymomas are the most aggressive of the thymomas.

Surgical resection is the favored treatment for thymoma. Complete surgical resection can be achieved for the vast majority of stage I and II thymomas. Stage III--IV thymomas that cannot be fully resected are generally treated with radiation and platinum-based combination chemotherapy regimens leading to substantial tumor shrinkage;^[@bib4],\ [@bib5],\ [@bib6],\ [@bib7]^ however, similar survival is observed with preoperative radiation therapy without chemotherapy.^[@bib8],\ [@bib9]^ Currently, there are no good biomarkers for response to therapy. Amplifications and rare activating mutations of EGFR and overexpression of *HER2*, *KIT*, *BCL2* and *TP53*, as well as loss of *CDKN2A* have been previously described.^[@bib7],\ [@bib10]^ However, no strong evidence supports response of thymomas to EGFR or KIT targeted therapies.^[@bib11]^

Thymomas and thymic carcinomas have been extensively profiled for chromosomal abnormalities, especially via comparative genomic hybridization,^[@bib12],\ [@bib13],\ [@bib14]^ revealing that the vast majority of B3 thymomas display chromosomal abnormalities. However, there is no information on tumorigenic point mutations in B3 thymomas.^[@bib7]^ Only a single genome sequence of a B3 thymoma has been reported thus far, for a tumor that displayed the typical chromosomal abnormalities for this tumor type (that is, gain of chromosome 1q, loss of chromosome 6 and 13q, and so on).^[@bib15]^ No mutations in common cancer-associated genes were observed, leading the authors to suggest that thymomas may evolve through distinct molecular mechanisms as compared with other tumor types. In this article, we report the identification of *DNMT3A* and *ASXL1* mutations in a cytogenetically normal stage IVB type B3 thymoma. This is the first identification of driver point mutations in B3 thymoma and suggests that further genomic profiling of cytogenetically normal B3 thymomas may reveal the specific molecular drivers of this tumor type.

Results
=======

The patient presented with a 3-month history of cough. He did not have shortness of breath, hemoptysis or weight loss at presentation. He also did not have neurologic symptoms consistent with myasthenia gravis. Family history is significant for thymoma in the mother. A computed tomography of the chest showed a mediastinal mass measuring 10.5 × 7.8 × 12.1 cm and a large (12 × 9.5 × 8.3 cm) left renal mass ([Figures 1a and 1b](#fig1){ref-type="fig"}, [](#fig1){ref-type="fig"}). The patient underwent computed tomography-guided biopsy of the mediastinal mass that revealed mildly atypical, uniform spindled cells associated with dense collagenous tissue. The tumor cells showed immunohistochemical positivity for AE1/AE3 and cytokeratin-7. Immunohistochemical markers for renal cell carcinoma were negative. The pathologic findings were consistent with thymoma. Subsequently, the patient underwent removal of mediastinal mass and right upper lobectomy as an en bloc resection. There was a separate right diaphragmatic nodule that was also excised. At the time of surgery, it was noted that the tumor was densely adherent to the pericardium and invaded the upper lobe of the right lung. Microscopic examination showed spindled to polygonal cells in varying sized lobules with accompanying fibrous bands of stroma invading the pericardium, pleura and lung ([Figures 1c and d](#fig1){ref-type="fig"}). Only occasional interspersed lymphocytes were seen. Focal lymph-vascular invasion was identified. The tumor cells showed ovoid nuclei with mild pleomorphism and scattered mitoses. The final margins were clear. The diaphragmatic nodule demonstrated tumor cells morphologically similar to the primary tumor. The final Masaoka stage of IVB was based on the finding of a separate distinct diaphragmatic tumor nodule and pleural invasion. The tumor had a WHO histologic category of B3 based on the predominance of epithelial cells and paucity of intraepithelial lymphocytes. No treatment was given before genome sequencing.

Tumor genome overview
---------------------

An overview of the somatic variants observed is presented in [Figure 1e](#fig1){ref-type="fig"}. Overall, 14 somatic indels and 176 somatic single-nucleotide polymorphisms were identified, 17 of which impacted the amino-acid sequence of proteins ([Table 1](#tbl1){ref-type="table"}). Sixteen copy number gains, 1 copy number loss ([Table 2](#tbl2){ref-type="table"}) and 6 structural variants ([Table 3](#tbl3){ref-type="table"}) were also observed. Sequencing of the renal mass revealed no overlap in somatic mutations, confirming the tumors were of independent origin. No major interchromosomal events were present in the thymoma genome, nor were any major chromosomal aneuploidies frequently observed in B3 thymomas.^[@bib12]^ Structural variants that were detected did not contain breakpoints within genes of known relevance to tumorigenesis ([Table 3](#tbl3){ref-type="table"}). Thus, somatic events of interest were comprised of point mutations and subchromosomal copy number variants.

Coding mutations
----------------

Fourteen nonsynonymous, 1 nonsense and 2 frameshift somatic mutations were observed in the tumor ([Table 1](#tbl1){ref-type="table"}). Of these mutations, four stood out with clear functional relevance---frameshift mutations in *FAM193A* and *ASXL1*, a nonsense mutation in *GRM5*, and a nonsynonymous mutation in *DNMT3A*. Although the mutations in FAM193A and GRM5 clearly impact protein function, the relevance of these mutations to tumorigenesis is not immediately apparent. On the other hand, the somatic mutations in *DNMT3A* and *ASXL1* are of the type previously observed in other tumor types and expected to contribute to tumorigenesis.

DNMT3A is a DNA methyltransferase required for *de novo* methylation and mammalian development.^[@bib16]^ It is known to act as a tumor suppressor in acute myeloid leukemia (AML) and is observed mutated less frequently in other tumor types.^[@bib17],\ [@bib18]^ The nonsynonymous mutation observed in this thymoma sample leads to a nonconservative substitution of aspartate for glycine at amino-acid 728 (p.G728D) within the DNA methylase domain of DNMT3A. This region is known to be responsible for the hydrophobic interaction between DNMT3A and its regulatory subunit DNMT3L, an interaction that is required for activation of DNMT3A methyltransferase activity and previously shown to be disrupted by mutations in this region.^[@bib19]^ Moreover, previously observed nonsynonymous mutations in AML cluster tightly within this region (shown in [Figure 2](#fig2){ref-type="fig"})^[@bib20],\ [@bib21],\ [@bib22]^. Strikingly and unusually, this somatic mutation was observed in homozygous state in the tumor: 61 of 62 (98.4%) exome sequencing reads from the tumor supported the mutation, 0 of 41 (0%) of exome sequencing reads from the normal sample supported the mutation, the homozygous state was confirmed via Sanger sequencing ([Figure 2,](#fig2){ref-type="fig"} inset), and no evidence for loss of heterozygosity was observed in the exome or low-pass whole-genome sequencing data. Moreover, no other somatic mutations were observed at \>60% allelic frequency in the tumor, suggesting a specific and early gene conversion event at this locus. Finally, a previously sequenced AML, reported by Hou *et al.*,^[@bib22]^ carried a mutation at this position (p.G728R) and at a nearby position (p.F731L), supporting the notion that homozygous or compound heterozygous mutations at the DNMT3A---DNMT3L interface are required to effectively disrupt methyltransferase activity.^[@bib23]^ Thus, the type, location and unusual zygosity of this somatic mutation strongly suggest mutations in *DNMT3A* have a causal role in the etiology of thymoma.

ASXL1 is a chromatin binding Polycomb group protein involved in transcriptional repression of numerous cell-type-specific systems, most likely through the recruitment of methylated histone H3 to promoters of target genes.^[@bib24]^ *ASXL1* is a known tumor suppressor in myelodysplastic syndrome and chronic myelomonocytic leukemia although it is frequently mutated in other tumor types such as lung squamous and bladder cancer.^[@bib17],\ [@bib18]^ The heterozygous deletion of a single guanine nucleotide within exon 12 of *ASXL1* leads to out-of-frame translation beginning at codon 657 and premature truncation of the protein, removing \>50% of the protein including the PHD domain responsible from histone interactions. This mutation was confirmed via Sanger sequencing ([Figure 3,](#fig3){ref-type="fig"} inset). Similar heterozygous C-terminal truncations are sufficient to induce myelodysplastic syndrome.^[@bib25]^ Previously observed frameshift or nonsense mutations in *ASXL1* across numerous tumor types catalogued in The Cancer Genome Atlas (TCGA) have been observed both upstream and downstream of amino-acid 657, with the highest concentration centered at position 657 ([Figure 3](#fig3){ref-type="fig"}). In fact, the majority of previously observed *ASXL1* mutations occur in the same exon as this mutation, exon 12.^[@bib26],\ [@bib27]^ Thus, both the type and location of this somatic mutation strongly suggests mutations in *ASXL1* have a causal role in the etiology of thymomas.

Copy number variants
--------------------

A number of focal copy number gains were observed in this tumor, the most interesting being an amplification of the *HOXA* cluster (see Discussion section).^[@bib28]^ Although a number of genes are known to be involved in tumorigenic processes are observed in these focal amplifications, no significance can be confidently assigned to these events.

Discussion
==========

Our results show that mutations in *DNMT3A* and *ASXL1* have a role in the development of thymoma. Our findings contrast starkly with a previous genome sequence from a B3 thymoma.^[@bib15]^ However, the previously reported thymoma displayed cytogenetic abnormalities commonly observed in B3 thymomas, whereas this tumor displayed largely normal cytogenetics. These results are reminiscent of the preferential occurrence of driver point mutations in cytogenetically normal AML and suggests further sequencing of cytogenetically normal thymomas are fertile ground for the identification of the molecular drivers of thymic cancer.^[@bib29]^ No obvious germline variant predisposing the patient to thymoma or renal cell cancer was observed, nor was there any overlap in somatic mutations between the thymoma and renal cell cancer to suggest shared etiology of these two tumors.

The first confidently identified driver mutation was a homozygous nonsynonymous mutation in *DNMT3A*. DNMT3A is a DNA methyltransferase essential for development, especially for *de novo* DNA methylation in stem cells.^[@bib16]^ *DNMT3A* is mutated in numerous tumor types, but is mutated especially frequently in AML.^[@bib20],\ [@bib21]^ DNMT3A and its binding partner, DNMT3L form a tetramer: DNMT3L:DNMT3A:DNMT3A:DNMT3L.^[@bib23]^ The most common DNMT3A mutations in AML occur at p.R882. Mutations at this position disrupt binding at the DNMT3A:DNMT3A interface, and impact activity in dominant-negative manner,^[@bib23],\ [@bib30]^ or at least reduce the odds of proper tetramer assembly by ∼75% as a single mutated DNMT3A protein is sufficient to disrupt tetramer assembly. Alternatively, the DNMT3L:DNMT3A interface is disrupted by somatic mutations within the mutational hotspot region centered on the p.G728D mutation observed in this thymoma.^[@bib23]^ Heterozygous mutations at this site may not be expected to influence activity as markedly as mutations at p.R882 as they likely allow for the formation of partially complete complexes, for example, DNMT3A:DNMT3A:DNMT3L complexes could form 50% of the time. Thus, it is notable that the p.G728D mutation was observed in homozygous state in this tumor. Homozygous somatic mutations are highly unusual, suggesting DNA repair via double-stranded break repair or synthesis-dependent strand annealing and/or some other gene conversion event occurred specifically at this site given we did not find any evidence for loss of heterozygosity.

The second confidently identified driver mutation was a frameshift mutation in exon 12 of *ASXL1*. ASXL1 is a known tumor suppressor in hematological malignancies, where the majority of frameshift and nonsense mutations are also observed in exon 12.^[@bib26],\ [@bib27]^ ASXL1 loss leads to loss of H3K27me3 and increased expression of genes repressed by these histone marks, especially the anterior HOXA gene cluster.^[@bib24]^ HOXA genes themselves are capable of leukemogenic transformation.^[@bib31]^ Interestingly, we also observe a concomitant and specific amplification of the HOXA gene cluster in this tumor.

It is intriguing that both *DNMT3A* and *ASXL1* are known tumor suppressors in hematological malignancies^[@bib18]^ and that the observed mutation characteristics are consistent with those seen in AML. However, both genes have been observed mutated, albeit at lower frequencies, in epithelial malignancies as well. Although co-occurrence of *DNMT3A* and *ASXL1* mutations are quite rare in epithelial and hematological malignancies, sequencing of a larger number of thymomas will be required to determine whether this co-occurrence is a happenstance of our subject selection or whether it points to a specific requirement of marked epigenetic reprogramming in the neoplastic transformation of thymic cells. The extent of *DNMT3A* and *ASXL1* mutations in thymoma should be explored, and treatments targeting epigenetic reprogramming should be considered in the future.

Materials and methods
=====================

Study consent
-------------

The study participant provided written informed consent under a protocol approved by the institutional review board of Scripps.

Tumor and normal sample
-----------------------

The formalin-fixed, paraffin-embedded block containing the thymoma tumor was sectioned 11 times, with each section placed on a separate slide. One section, at 4-μm thick, was stained and used to assess tumor area and cellularity. The boundaries of the tumor were marked, and the tumor cellularity was estimated to be \>85%. The additional 10 sections were cut at 10-μm thicknesses, and the designated (the boundaries were traced onto each slide using the stained and marked slide) tumor areas were extracted and isolated using the RecoverAll FFPE nucleic acid isolation kit (Ambion, Austin, TX, USA). Freshly drawn blood was obtained for the analysis of normal DNA. Genomic DNA was extracted from whole blood using the QIAamp system (Qiagen, Valencia, CA, USA). Sequence alignment and variant calling were performed against the reference human genome (NCBI 37/hg 19).

Whole-exome sequencing, variant calling and filtration
------------------------------------------------------

Whole-exome sequencing was pursued utilizing Agilent SureSelect exome hybridization followed by barcoding and sequencing of paired 100-bp reads on the equivalent of ∼1 lane of an Illumina HiSeq2500 (Illumina, San Diego, CA, USA) instrument (samples were barcoded and distributed across multiple lanes). Read mapping and initial variant calling and quality filtration was performed using the standard BWA-GATK^[@bib32],\ [@bib33]^ best practices variant quality score recalibration approach. A mean coverage of 157.3X and 98.7X was achieved for the tumor and normal sample with 96.1% and 98.7% of the target exome covered by \>10 reads, respectively.

Somatic point mutations were detected using MUTECT.^[@bib13]^ Somatic indels were detected using SomaticIndelDetector.^[@bib32]^ Somatic variants were then annotated using the SG-ADVISER (genomics.scripps.edu/ADVISER/) and Cypher Genomics, Inc. (San Diego, CA, USA) systems for further filtration. Somatic variants present at \>0.1% frequency in the HapMap,^[@bib14]^ 1000 Genomes,^[@bib34]^ NHLBI GO Exome Sequencing Project,^[@bib35]^ or 385 genomes from the Scripps Wellderly population, as well as variants present in segmental duplication regions that are prone to produce false-positive variant calls were removed. Somatic indels were stringently filtered to remove indels within simple repeats, repeats identical to the inserted/deleted sequence or adjacent to homopolymer repeats of length 5+. Nonsynonymous, in-frame, frameshift, nonsense or canonical splice-site donor/acceptor site variants were retained for further analysis.

Low-pass whole-genome sequencing, structural variant calling and filtration
---------------------------------------------------------------------------

Low-pass whole-genome sequencing was performed by barcoding and sequencing of paired 100-bp reads on the equivalent of ∼1 lane of an Illumina HiSeq2500. A mean coverage of 7.4X and 7.7X was achieved for the tumor and normal sample with 92.0% and 95.5% of the genome covered by \>3 reads, respectively. Copy number and structural variants were identified by SVDetect.^[@bib36]^ For copy number variants, read density was determined for 100-kb windows at 10-kb intervals. The significance of read density differences between the tumor and normal sample were determined using a binomial test with the normal sample determining the probability of read mapping per window in order to adjust for mapability and other window-specific effects. Significant windows (*P*-value threshold=1E--8) were stringently filtered to retain called copy number variations only where the ratio of tumor to normal reads, adjusted for the difference in total number of reads, was at least 1.5X greater for copy number gains or 0.5X lower for copy number losses. For structural variants, an initial set of raw candidate structural variants was called using SVDetect with at least seven reads supporting structural variant calls in the tumor sample and three reads supporting calls in the normal sample. Tumor sample candidate structural variants were then filtered to remove structural variants with support in the normal sample or mapping to centromeric regions.

Circos plots were generated via RCircos.^[@bib37]^ Mutation plots were generated via adaption of cBioPortal visualization plots.^[@bib38]^
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![(**a**) Thymoma imaging. fluorodeoxyglucose positron emission tomography/computed tomography (CT) demonstrates intensely hypermetabolic anterior mediastinal mass on fused coronal and axial images (arrowheads). Cystic tumor component on attenuation-correction CT image is non-hypermetabolic on FDG PET (arrows). (**b**) Renal tumor imaging. CT scan with contrast (left) demonstrates large contrast-enhancing left renal mass (arrowheads) with posterior hydronephrotic upper pole collecting system (block arrow). Fused axial FDG PET/CT (right) demonstrates mildly hypermetabolic posterior tumor component (arrow). Upper pole hydronephrosis contains excreted urinary FDG (block arrow). (**c, d**) Thymoma histology. (**c**) Lobules of thymoma tumor cells infiltrate into the adjacent lung parenchyma (arrows: hematoxylin and eosin (H&E): × 5 magnification). (**d**) Sheets of thymoma type B3 polygonal tumor cells with ovoid nuclei (H&E: × 20 magnification). (**e**) Tumor genome overview. Circos plot overview of somatic mutations identified in the thymoma. Outer text denotes location and gene impacted by somatic protein coding mutations. Middle gray ring depicts copy number variation (CNV) status (black=2 copies, red=CNV gains, blue=CNV losses). Inner text displays genes overlapping identified CNVs. Inner red lines display identified structural variants.](oncsis201425f1){#fig1}

![The DNMT3A p.G728D mutation observed in this thymoma sample is visualized in the context of other DNMT3A mutations observed in AML genome sequences from TCGA. The protein sequence and functional domains are depicted on the *x* axis. The number of AML mutations is depicted on the *y* axis. Red circles correspond to truncating mutations. Green circles correspond to missense mutations. Circle height corresponds to the number of mutations per position, however, the G728D indicator (black) is only meant to indicate position of this mutation. Note the clustering of AML nonsynonymous mutations around position 728. Mutations in this region reduce DNMT3A activity by disrupting the interaction between DNMT3L and DNMT3A. The Sanger sequencing validation trace of p.G7238D is also shown, demonstrating validation of p.G7238D as a homozygous somatic mutation.](oncsis201425f2){#fig2}

![The ASXL1 p.E657fs mutation observed in this thymoma sample is visualized in the context of other ASXL1 mutations observed in all tumor genome sequences catalogued in TCGA. The protein sequence and functional domains are depicted on the *x* axis. The number of TCGA mutations is depicted on the *y* axis. Red circles correspond to truncating mutations. Green circles correspond to nonsynonymous mutations. Purple circles correspond to mutations that are both nonsynonymous and truncating in different gene isoforms. Circle height corresponds to the number of mutations per position, however, the E657fs indicator (black) is only meant to indicate position of this mutation. Note the clustering of TCGA truncating mutations around position 657. The Sanger sequencing validation trace of p.E657fs is also shown, demonstrating validation of p.E657fs as a heterozygous somatic mutation.](oncsis201425f3){#fig3}

###### Coding mutations

  *Gene*    *Gene impact*    *Protein location*  *Prediction of impact*   *Coordinates (hg19)*
  --------- --------------- -------------------- ------------------------ -----------------------------
  ALDH1A3   Missense                T51I         SIFT, Condel             chr15: 101 425 524 snp C\>T
  AP3M2     Missense                H19N         Polyphen, SIFT, Condel   chr8: 42 012 260 snp C\>A
  ASXL1     Frameshift             E657fs        Damaging                 chr20: 31 022 486 del G\>-
  ATRIP     Missense                G21R         SIFT, Condel             chr3: 48 488 310 snp G\>C
  DNAJB12   Missense               L292V         Neutral                  chr10: 74 098 021 snp G\>C
  DNMT3A    Missense               G728D         Polyphen, SIFT, Condel   chr2: 25 463 310 snp C\>T
  FAM193A   Frameshift             H303fs        Damaging                 chr4: 2 648 428 ins -\>T
  GRM5      Nonsense               R351\*        Damaging                 chr11: 88 386 432 snp G\>A
  HECTD3    Missense                R14P         SIFT, Condel             chr1: 45 476 889 snp C\>G
  JPH2      Missense               V239M         Neutral                  chr20: 42 788 712 snp C\>T
  MAGI2     Missense               R375Q         Condel                   chr7: 77 807 386 snp C\>T
  MORC1     Missense               R597H         Neutral                  chr3: 108 724 077 snp C\>T
  NCALD     Missense               R181C         Polyphen, SIFT, Condel   chr8: 102 701 578 snp G\>A
  PVRL1     Missense               L360V         Neutral                  chr11: 119 510 648 snp G\>C
  SH3BP1    Missense               T626P         Neutral                  chr22: 38 051 466 snp A\>C
  TBC1D8    Missense               R144G         Neutral                  chr2: 101 670 771 snp T\>C
  TBKBP1    Missense                K75T         Polyphen, SIFT, Condel   chr17: 45 773 702 snp A\>C

Somatic protein coding mutations.

###### Copy number variants

  *Type*   *Coordinates*                     *Size (kb)*   *Dosage*   *Overlapping genes*
  -------- --------------------------------- ------------- ---------- ------------------------------
  Gain     chr1: 470 001--600 000            130           5          None
  Gain     chr2: 145 130 001--145 310 000    180           3          ZEB2
  Gain     chr2: 158 260 001--158 370 000    110           3          CYTIP
  Gain     chr2: 192 770 001--192 940 000    170           3          TMEFF2
  Gain     chr2: 240 110 001--240 240 000    130           3          HDAC4
  Gain     chr4: 153 220 001--153 320 000    100           3          FBXW7
  Gain     chr7: 27 120 001--27 240 000      120           3          HOXA gene cluster, MIR196B
  Gain     chr7: 38 290 001--38 390 000      100           3          TARP
  Gain     chr8: 142 200 001--142 320 000    120           3          SLC45A4, DENND3
  Gain     chr9: 75 690 001--75 830 000      140           3          ANXA1, ALDH1A1
  Gain     chr9: 139 420 001--139 520 000    100           3          NOTCH1, MIR4674
  Gain     chr13: 114 740 001--114 920 000   180           3          RASA3
  Gain     chr15: 99 410 001--99 510 000     100           3          IGF1R
  Gain     chr17: 80 740 001--80 920 000     180           3          TBCD, ZNF750, B3GNTL1
  Loss     chr19: 54 070 001--54 200 000     130           1          ZNF331, DPRX, MIR520 cluster
  Gain     chr21: 44 690 001--44 900 000     210           3          SIK1
  Gain     chr22: 46 380 001--46 550 000     170           3          MIRLET7B, MIR3619, MIR4763

Tumor-specific copy number variants, dosage and contained genes.

###### Structural variants

  ------------ --------- -------------------------------- -------------------------------- ---------------------
  *Type*        *State*  *Breakpoint 1*                   *Breakpoint 2*                    *Overlapping genes*
  Coamplicon      Bal    chr16: 26 382 735--26 386 932    chr16: 26 382 736--26 386 932            None
  Inversion      Unbal   chr2: 87 651 839--87 656 090     chr2: 90 482 288--90 485 529             Many
  Inversion      Unbal   chr2: 33 141 477--33 141 679     chr2: 242 819 853--242 820 060           Many
  Coamplicon      Bal    chr7: 158 706 424--158 710 034   chr7: 158 706 425--158 710 035           WDR60
  Insertion       Bal    chr7: 158 704 999--158 708 434   chr7: 158 705 000--158 709 994           WDR60
  Insertion       Bal    chr9: 139 994 967--139 997 831   chr9: 139 994 968--139 998 202          MAN1B1
  ------------ --------- -------------------------------- -------------------------------- ---------------------

Abbreviations: Bal, balanced; Unbal, unbalanced.

Tumor-specific structural variants.
